Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (07/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.

Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer (07/09/2010)
The combination of the investigational agent trabectedin with pegylated liposomal doxorubicin (PLD) resulted in a 1.5-month improvement in progression-free survival in women with recurrent ovarian cancer.

High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (07/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.

Promising Results for Ovarian Cancer Screening Strategy (06/03/2010)
In a study of postmenopausal women at average-risk of ovarian cancer, promising results were obtained with an ovarian cancer screening strategy that combined information about trends in CA-125 blood test results and age, followed as needed by transvaginal ultrasound and referral to a gynecologic oncologist. These results will be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

Continued Chemotherapy in Advanced Ovarian Cancer (08/09/2010)
Continuing chemotherapy following initial treatment of advanced ovarian cancer may improve survival, according to a study published in Cancer.

Olaparib Shows Promise in High-grade Serous Ovarian Cancer (06/16/2010)
Advanced serous ovarian cancer responds to single-agent treatment with olaparib, according to the results of a Phase II study presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Chemotherapy Drug Patupilone Fails in Advanced Ovarian Cancer (06/02/2010)
The chemotherapy drug patupilone (EPO906) has failed to show a survival advantage over Doxil®/Caelyx® (pegylated liposomal doxorubicin) in patients with advanced ovarian cancer that is resistant to platinum-based therapy. Novartis reported the results in a press release